New gel could scratch the itch from cancer treatment
NCT ID NCT06748404
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether TriCalm Hydrogel, an over-the-counter gel, can reduce itching caused by immune checkpoint inhibitors used in cancer therapy. About 28 adults with grade 1-3 itch will use either the gel or a standard steroid cream for one cycle. The study measures how well the gel controls itch and improves quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TriCalm Hydrogel (aluminum acetate 0.2% and strontium chloride hexahydrate)
- What this could lead to
- If it works, this could offer a non-steroid option to relieve itching from immunotherapy, improving comfort and quality of life for cancer patients.
- What could go wrong
- This is a small, early-phase trial with only 28 people, so results may not apply to everyone. It's testing symptom relief, not a cure, and the gel may not work better than standard steroid cream.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY-RELATED PRURITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of California San Diego
RECRUITINGLa Jolla, California, 92037, United States
Contact Email: •••••@•••••